Media.Player

A-18 Novel Method to Produce Mesenchymal Stem Cells

Technology Benefits

ΓùÅ Novel: This is a novel method to isolate ADSCs from adipose cellsΓùÅ Patient-Friendly: ADSCs can be produced from patientΓÇÖs own embryo or skin cellsΓùÅ Diversified Applications: ADSCs can be differentiated into adipose, osteoblast, skeletal muscle and chondrocytes.

Technology Application

ΓùÅ Regenerative medicine (adipose, osteoblast, skeletal muscle and chondrocyte)ΓùÅ Transplantation for arterial sclerosis, cardial infarcts, hepatocirrhosis, diabetes, ParkinsonΓÇÖs disease and muscular dystrophy patientsΓùÅ Research tools for lab technicians

Detailed Technology Description

None

Supplementary Information

Inventor: TORIHASHI, Shigeko | NINAGAWA, Nana
Priority Number: WO2009128533A1
IPC Current: C12N00050775 | C12N000510
Assignee Applicant: National University Corporation Nagoya University
Title: MESENCHYMAL STEM CELL AND METHOD FOR PRODUCTION THEREOF | CELLULE SOUCHE MÉSENCHYMATEUSE ET SON PROCÉDÉ DE PRODUCTION
Usefulness: MESENCHYMAL STEM CELL AND METHOD FOR PRODUCTION THEREOF | CELLULE SOUCHE MÉSENCHYMATEUSE ET SON PROCÉDÉ DE PRODUCTION
Summary: The cell culture product is useful in regeneration medicine for treating diseases such as life-style related diseases, e.g. arteriosclerosis, myocardial infarction, liver cirrhosis, diabetes, Parkinson's disease and muscular dystrophy.
Novelty: Cell culture product in regeneration medicine for treating diseases e.g. diabetes, comprises mesenchymal stem cell of cluster of differentiation 105 positive cell differentiated from pluripotent stem cell derived from human or animal

Industry

Biomedical

Sub Category

Bioengineering

*Abstract

Researchers at Nagoya University have developed a novel method to produce mesenchymal stem cells. Because of its differentiation capability into adipose, osteoblast, skeletal muscle and chondrocytes, mesenchymal stem cells (MCS) are highly expected to be applied to regenerative medicine. Adipose-derived stem cells (ADSCs) can be obtained from patient bone marrow. However, the method to produce ADSCs from other human tissues is now getting more attention because only a limited amount of ADSCs can be isolated from bone marrow. In this invention, a novel and efficient method was found to isolate ADSCs from adipose cells differentiated from ES cells or iPS cells using anti-CD105 antibody. This technology could become very useful for transplantation because ES and iPS cells can be obtained from patients and they will not cause a rejection response.

*Principal Investigator

Name: Shigeko Torihashi, PhD, Professor

Department: School of Health Sciences Physical Therapy at Nagoya University, Japan

Country/Region

USA